Cure Today

ROS1-Positive NSCLC Represents a Targetable Mutation for New Therapies

An expert explained what ROS1-positive non-small cell lung cancer is and why it is important to identify mutations like ROS1 through genetic sequencing. ROS1-positive non-small cell lung cancer, a ...
ascopubs.org

Ten Years After Mutation Testing for Lynch Syndrome: Cancer Incidence and Outcome in Mutation-Positive and Mutation-Negative Family Members

Phase III Study of Pemetrexed Plus Carboplatin Compared With Etoposide Plus Carboplatin in Chemotherapy-Naive Patients With Extensive-Stage Small-Cell Lung Cancer Cancer incidence and survival were ...
ascopubs.org

Multi-Regional Profiling of Epidermal Growth Factor Receptor L858R Mutation-Positive Metastatic Renal Pelvic Cancer Successfully Treated With Osimertinib

The patient was a 70-year-old male with a 2-year history of asymptomatic gross hematuria. Computed tomography (CT) revealed a right renal mass, multiple lung metastases, and enlarged lymph nodes, ...
Monthly Prescribing Reference

Tagrisso Approved for First-Line Tx of EGFR Mutation Positive Advanced NSCLC

Credit: AstraZeneca. Tagrisso, a kinase inhibitor, is available as 40mg and 80mg strength tablets in 30-count bottles. The Food and Drug Administration (FDA) has approved Tagrisso ® (osimertinib) in ...
Targeted Oncology

Navigating Complexity: Key Updates to ASCO's Living Guidelines for Stage IV Driver Mutation–Negative NSCLC

The updated ASCO living guideline for stage IV driver mutation–negative NSCLC does not offer a single, simple answer, and ...
NBC News

Pfizer’s Lorbrena extends life for patients with rare lung cancer

Pfizer’s lung cancer drug Lorbrena can extend life for patients with a rare form of the disease for years longer than other drugs, according to new research published Friday. The drug treats a type of ...
Business Wire

FDA Approves Genentech’s Itovebi, a Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation

– Approval is based on Phase III INAVO120 results, showing the Itovebi TM (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the ...
AOL

Mom writes another children's book after testing positive for BRCA2 mutation

Ashley Dedmon’s parents always told her knowledge is power. Discussions about health, she says, were the norm growing up. “They were educators,” Dedmon says of her parents. “They were always wanting ...
Seeking Alpha

Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa

MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and ...